Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression, and spread of cancer. Small molecule medicines are small enough to slip inside cancer cells and destroy them. Small molecule cancer drugs, because of their small size, have been successfully used to target the extracellular, cell surface ligand-binding receptors as well as the intracellular proteins, including anti-apoptotic proteins that play a key role in transducing downstream signalling for cell growth and metastasis promotion. Research on molecularly targeted cancer drug discovery over the last few decades has resulted in a number of small molecule drugs being successfully introduced in the clinic for cancer treatment. Most of these drugs inhibit critical cancer targets such as serine, threonine, tyrosine kinases, and matrix metalloproteinases (MMPs), heat shock proteins (HSPs), proteosome and other proteins playing a role in signal transduction pathways.
The global small molecule targeted cancer therapy market is witnessing significant growth owing to rise in incidence rate of cancer, minimal adverse effects and high adoption rate. There has been tremendous innovation over the past decade with the emergence of new drugs with very promising efficacy, along with increasing adoption of precision medicine technologies, as well as advanced monitoring techniques such as liquid biopsy. Moreover, advances in molecular and genomic research have revealed underlying complexities and provided insights into cancer. Continued research has expanded knowledge of how the disease develops and how to target medicines for specific cancer types, resulting in more effective therapies for patients.
The report analyses the global small molecule targeted cancer therapy market based on type, cancer type and geography.
Based on type, the market is categorized into monoclonal antibodies including fully human antibody, chimeric monoclonal antibody, humanized monoclonal antibody; small molecules such as, small molecule cyclin-dependent kinase inhibitor, small molecule proteasome inhibitor and small molecule tyrosine kinase inhibitor; and small molecule drug conjugates. Receptor tyrosine kinases (RTKs) are often preferred as key targets for anti-cancer drugs as aberrant activation of these usually result in downstream signalling that involves activation of pivotal cytoplasmic kinases which are usually serine/threonine kinases (STKs).
By various cancer types, the global small molecule targeted cancer therapy market is segmented into lung cancer, breast cancer, colorectal cancer, leukemia, lymphoma, melanoma, prostate cancer and others. About 20% to 25% of all breast cancers have too much of a protein called human epidermal growth factor receptor 2 (HER2, pronounced her-too). This protein makes tumor cells grow. If the cancer is HER2 positive, several targeted therapies are available.
By geography, the global small molecule targeted cancer therapy market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America dominated the global small molecule targeted cancer therapy market in 2018. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly. The industry has seen several recent changes including growing competition, rise in merger and acquisition activities, increased cancer health insurance coverage, and an increasing amount of foreign direct investment. Also, Asia-Pacific is anticipated to be the fastest growing region during the forecast period. This market is hugely driven by rising demand and investment level of government. In more developed region such as Japan and China, the offerings from the market players are expected to be diverse, focused mainly on customized demands. Additionally, the market is predicted to witness expansion in terms of the newer forms of drugs because of rising cancer incidence and growing awareness.
The leading market players of the global small molecule targeted cancer therapy market are Abbott Laboratories, Bayer AG, Boehringer Ingelheim GmbH, Sanofi, GlaxoSmithKline plc, AstraZeneca PLC, OncoGenex Pharmaceuticals Inc., Pfizer, Inc., AVEO Pharmaceuticals Inc. and Cytokinetics Inc. In June 2018, Bayer AG and the University of Texas MD Anderson Cancer Center signed a five-year collaboration agreement to accelerate the development of novel targeted treatments based on patient or tumor characteristics for which current therapies have not shown satisfactory clinical efficacy. Moreover, in July 2018, Sanofi and REVOLUTION Medicines, Inc. announced an exclusive partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations.
The global small molecule targeted cancer therapy market is segmented based on type, cancer type and geography. Based on type, the market is categorized into monoclonal antibodies including fully human antibody, chimeric monoclonal antibody, humanized monoclonal antibody; small molecules such as, small molecule cyclin-dependent kinase inhibitor, small molecule proteasome inhibitor and small molecule tyrosine kinase inhibitor; and small molecule drug conjugates.
By various cancer types, the global small molecule targeted cancer therapy market is segmented into lung cancer, breast cancer, colorectal cancer, leukemia, lymphoma, melanoma, prostate cancer and others.
By geography, the global small molecule targeted cancer therapy market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America dominated the global small molecule targeted cancer therapy market in 2018. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly.
Why to buy this report:
